Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL. Burger JA, Barr PM, Robak T, Owen C, et al. Blood 2025;146:2168-2176.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Burger JA, Barr PM, Robak T, Owen C, et al. Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL. Blood 2025;146:2168-2176.
PMID: 40737596